Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts.

Archives: Reports

MARA Rating Company
December 16, 2025

Benlysta / belimumab for treating active autoantibody-positive systemic lupus erythematosus as of December 2021

MARA Rating Company December 16, 2025

Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over as of February 2024

MARA Rating Company December 16, 2025

Welireg / belzutifan for treating tumours associated with von Hippel-Lindau disease as of October 2024

MARA Rating Company December 16, 2025

Nilemdo / bempedoic acid for treating primary hypercholesterolaemia or mixed dyslipidaemia as of April 2021

MARA Rating Company December 16, 2025

Orladeyo / berotralstat for preventing recurrent attacks of hereditary angioedema as of October 2021

MARA Rating Company December 16, 2025

Bevacizumab gamma / lytenava for treating wet age-related macular degeneration as of December 2024

MARA Rating Company December 16, 2025

Bimzelx / bimekizumab for treating moderate to severe plaque psoriasis as of September 2021

MARA Rating Company December 16, 2025

Bimzelx / bimekizumab for treating active psoriatic arthritis as of October 2023

MARA Rating Company December 16, 2025

Bimzelx / bimekizumab for treating axial spondyloarthritis as of October 2023

MARA Rating Company December 16, 2025

Blinatumomab for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia as of March 2025

MARA Rating Company December 16, 2025